GSK Signs On As Shire’s Vyvanse Promotion Partner
This article was originally published in The Pink Sheet Daily
Executive Summary
Addition of GSK’s 600 sales reps will more than double the reach of Shire’s current promotional effort for the ADHD medication.
You may also be interested in...
Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market
In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications
Attention Getter: Shire Focuses on Vyvanse and the Adult ADHD Market
In just a few weeks, schools will close for summer, a time when parents and caregivers have less reason to ensure many children are taking ADHD medications
ADHD Market Snapshot: Changes Blow In With Adderall XR Generics
The first generic versions of Shire's market-leading attention deficit/hyperactivity disorder medication Adderall XR (amphetamine extended release) are expected to hit the market April 1. This will deliver a kick to the remaining branded drugs in the category - though not as swiftly as some might expect